Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
500 participants
OBSERVATIONAL
2019-03-04
2026-06-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
NCT00830557
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT05687188
Project Survival-Prospective Biomarker Discovery
NCT02781012
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT04275557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this research study, the investigators want to partner with individuals known or suspected to have pancreatic cancer to build a 'biobank' dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. A biobank is a valuable resource that involves collection, processing, and storage of blood, other bodily fluids, and tissue (obtained during biopsy or surgery) to improve the investigator's understanding of health and disease. When combined with information and medical images obtained through routine care, the investigators will be able to investigate biological processes that may underlie differences and poor outcomes and target them with more effective therapeutic strategies tailored to the individual.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All Participants
Blood samples, tumor samples and data will be collected from all participants as applicable.
Blood Sample Collection
Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
Tumor Sample collection
At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
Data Collection
Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Sample Collection
Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
Tumor Sample collection
At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
Data Collection
Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient presents for evaluation at a participating site with a strong clinical suspicion or diagnosis of a pancreatic cancer primary based on symptoms, imaging, biopsy, and/or blood-work and has not had treatment.
* Patient self-reports as Non-Hispanic White, African American, or Hispanic.
* Able to understand and voluntarily sign the informed consent.
* Willing to complete study questionnaire(s) and donate medical images and biological specimens (including tissue and blood) obtained at the time of standard of care procedures (biopsy, surgery, and/or venipuncture) after signing the informed consent document.
Exclusion Criteria
* Has a diagnosis of pancreatic cancer but and has already undergone treatment (which may include surgery, chemotherapy, and/or radiation).
* Self-reported race/ethnicity other than Non-Hispanic White, African American, or Hispanic.
* Unable to provide informed consent.
* Unwilling to complete study questionnaires(s) and/or donate biological specimens
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Permuth, PhD
Role: PRINCIPAL_INVESTIGATOR
H. Lee Moffitt Cancer Center and Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lee Memorial Hospital Regional Cancer Center
Fort Myers, Florida, United States
University of Florida - Gainesville
Gainesville, Florida, United States
Palmetto General Hospital
Hialeah, Florida, United States
University of Florida - Jacksonville
Jacksonville, Florida, United States
Lakeland Regional Health
Lakeland, Florida, United States
Sylvester Comprehensive Cancer Center & Jackson Memorial Hospital
Miami, Florida, United States
Mount Sinai Medical Center
Miami Beach, Florida, United States
Advent Health - Orlando
Orlando, Florida, United States
University of Florida - Orlando
Orlando, Florida, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
St Anthony's Baycare/Bay Surgical Specialists
St. Petersburg, Florida, United States
Tallahassee Memorial Healthcare
Tallahassee, Florida, United States
University of South Florida/Tampa General Hospital
Tampa, Florida, United States
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8JK02
Identifier Type: OTHER
Identifier Source: secondary_id
MCC-19717
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.